Community medicine short notes on the following topics....Epidemiological parameters used in malaria surveillance, Treatment of P. Vivax and P. falciparum, Integrated vector management, Twin pillars of Lymphatic filariasis elimination strategy
Reading Document
Medical Text Search
epidemiological parameters malaria surveillance API ABER SPR
Medical Text Search
treatment P. vivax P. falciparum malaria chloroquine artemisinin primaquine
GradeResponse
GradeResponse
Medical Text Search
integrated vector management malaria IVM components
Medical Text Search
lymphatic filariasis elimination strategy twin pillars MDA morbidity management
Here are comprehensive short notes on all four topics:
1. Epidemiological Parameters Used in Malaria Surveillance
Malaria surveillance generates data used for planning, monitoring, evaluating programmes, detecting epidemics, and supporting elimination certification (WHO Malaria Surveillance, p. 253).
Key Indices
A. Parasitological Indices
| Parameter | Formula | Significance |
|---|---|---|
| Slide Positivity Rate (SPR) | (Positive slides / Total slides examined) × 100 | Reflects transmission intensity; used to assess burden |
| Slide Falciparum Rate (SFR) | (P. falciparum slides / Total slides examined) × 100 | Proportion of falciparum among positives |
| Blood Examination Rate (BER) | (Slides examined / Population) × 1000 / year | Measures program effort and coverage |
B. Incidence Indices
| Parameter | Formula | Significance |
|---|---|---|
| Annual Parasite Incidence (API) | (Confirmed malaria cases / Population) × 1000 / year | Most important surveillance index; used for stratification |
| Annual Blood Examination Rate (ABER) | (Blood slides examined / Population) × 100 / year | Reflects surveillance activity; target ≥10% |
| Annual Falciparum Incidence (AFI) | (Confirmed P. falciparum cases / Population) × 1000 / year | Tracks severe malaria risk |
C. Entomological Indices
- Man Biting Rate (MBR): Number of bites per person per night
- Entomological Inoculation Rate (EIR): Number of infective bites per person per year
- Sporozoite Rate: % of mosquitoes carrying sporozoites in salivary glands
D. Programme Performance Indices
- Reporting completeness: % of health facilities reporting on time
- Case fatality rate (CFR): Deaths / confirmed cases × 100
Stratification by API (India/NVBDCP)
- API < 1: Low transmission
- API 1–2: Moderate transmission
- API > 2: High transmission (High Burden Districts — HBDs)
2. Treatment of P. vivax and P. falciparum
P. vivax Treatment
Uncomplicated P. vivax
| Drug | Dose | Duration |
|---|---|---|
| Chloroquine (drug of choice) | 10 mg/kg Day 1 & 2; 5 mg/kg Day 3 | 3 days |
| Primaquine (radical cure — prevents relapse) | 0.25 mg/kg/day (standard); 0.5 mg/kg/day (high relapse areas) | 14 days |
- Primaquine eliminates hypnozoites (liver-dormant forms) — essential to prevent relapse
- Screen for G6PD deficiency before primaquine (causes hemolysis in G6PD-deficient patients)
- Where chloroquine resistance exists: ACT + Primaquine (e.g., Artemether-Lumefantrine or DHA-Piperaquine)
- ACTs achieve rapid initial response but relapses follow if primaquine is omitted (Malaria, p. 191)
Chloroquine-Resistant P. vivax
- ACT (Artemether + Lumefantrine or DHA + Piperaquine) + Primaquine 14 days
- Recurrences occur earlier after Artemether-Lumefantrine than DHA-Piperaquine due to faster elimination of lumefantrine (Malaria, p. 191)
P. falciparum Treatment
Uncomplicated P. falciparum
Artemisinin-based Combination Therapy (ACT) — first-line worldwide
| ACT Regimen | Dose | Duration |
|---|---|---|
| Artemether + Lumefantrine (AL) | 1.5/9 mg/kg twice daily | 3 days |
| Artesunate + Amodiaquine (AS+AQ) | 4 mg/kg + 10 mg/kg daily | 3 days |
| Artesunate + Mefloquine (AS+MQ) | 4 mg/kg + 8.3 mg/kg daily | 3 days |
| Dihydroartemisinin + Piperaquine (DHA-PPQ) | 4 mg/kg + 18 mg/kg daily | 3 days |
| Artesunate + SP | Not preferred where SP resistance exists |
- Add single-dose Primaquine (0.25 mg/kg) to block gametocytes and reduce transmission (WHO policy)
- ACTs exploit artemisinin's rapid parasite clearance + partner drug's longer half-life to prevent recrudescence
Severe/Complicated P. falciparum
| Drug | Route | Notes |
|---|---|---|
| IV Artesunate | IV | First choice — superior to quinine (AQUAMAT/SEAQUAMAT trials) |
| IV Quinine + Doxycycline | IV | Alternative when artesunate unavailable |
| IM Artesunate / IM Artemether | IM | Pre-referral use in peripheral settings |
- Supportive care: IV fluids, antipyretics, management of hypoglycemia, seizures, renal failure, pulmonary edema
India (NVBDCP) Protocol
- P. vivax: Chloroquine 3 days + Primaquine 14 days
- P. falciparum: ACT (AL) 3 days + single-dose Primaquine Day 2
- Mixed infection (P.v + P.f): Full ACT + Primaquine 14 days
3. Integrated Vector Management (IVM)
Definition
IVM is a rational decision-making process to optimize use of resources for vector control. It considers the health sector, other sectors, the community, and use of a range of interventions — alone or in combination — to achieve a sustainable reduction in vector populations and disease transmission.
Five Core Elements (WHO Framework)
| Element | Description |
|---|---|
| Advocacy, social mobilization & legislation | Community engagement, political commitment, legal support |
| Collaboration within the health sector & with other sectors | Integration with water management, agriculture, urban planning |
| Evidence-based decision-making | Epidemiological & entomological data guide choice of interventions |
| Capacity building | Training human resources at all levels |
| Research | Operational research to improve effectiveness |
Main Vector Control Interventions
1. Indoor Residual Spraying (IRS)
- Application of residual insecticide to indoor walls and ceilings
- Effective against endophilic (indoor resting) mosquitoes
- Classes: Pyrethroids, organophosphates, carbamates
- Coverage target: ≥85% of eligible structures
2. Long-Lasting Insecticidal Nets (LLINs)
- Bed nets treated with pyrethroid insecticides lasting ≥20 washes
- Reduce biting and kill mosquitoes
- Priority for: Pregnant women, children under 5
3. Larval Source Management (LSM)
- Environmental management: Drainage, filling, modification of breeding sites
- Larviciding: Application of biological (Bacillus thuringiensis israelensis — Bti; Bacillus sphaericus) or chemical larvicides
- Biocontrol: Introduction of larvivorous fish (Gambusia, Guppy) in permanent water bodies
4. Space Spraying (Fogging)
- Thermal or ultra-low volume (ULV) spraying of insecticides
- Used during outbreaks; less effective for sustained control
5. Personal Protection
- Repellents (DEET, picaridin), protective clothing, screened windows/doors
Rationale for IVM
- Avoids over-reliance on a single intervention
- Reduces insecticide resistance through rotation
- Maximizes cost-effectiveness
- Promotes inter-sectoral coordination (agriculture, water, housing)
- Environmentally sustainable
4. Twin Pillars of Lymphatic Filariasis Elimination Strategy
The Global Programme to Eliminate Lymphatic Filariasis (GPELF), launched by WHO in 2000, is built on two complementary pillars:
Pillar 1: Interrupting Transmission — Mass Drug Administration (MDA)
Objective
Reduce the microfilarial load in the community to levels too low to sustain transmission by Culex, Anopheles, or Aedes mosquitoes.
Drug Regimens
| Setting | Regimen | Frequency |
|---|---|---|
| Non-endemic for loiasis | Albendazole 400 mg + Ivermectin 150–200 mcg/kg | Annual × minimum 5 years |
| Co-endemic with onchocerciasis | Albendazole 400 mg + Ivermectin | Annual |
| Where Loa loa is present | Albendazole 400 mg alone | Annual |
| IDA regimen (newer) | Ivermectin + Diethylcarbamazine (DEC) + Albendazole | Single round may suffice |
- DEC + Albendazole is the standard regimen in areas without onchocerciasis (e.g., India, Africa regions without loiasis)
- DEC-fortified salt is an alternative in India and some Pacific islands
Geographic Coverage
- Target coverage: ≥65% of total population in endemic implementation units
- Minimum of 5 annual rounds before transmission assessment surveys (TAS)
Mechanism
- DEC: Kills microfilariae and some adult worms
- Ivermectin: Potent microfilaricidal; reduces skin/lymphatic microfilaremia
- Albendazole: Macrofilaricidal activity; kills adult worms over time; also treats soil-transmitted helminths
Pillar 2: Alleviating Suffering — Morbidity Management and Disability Prevention (MMDP)
Objective
Reduce and prevent disability in people already affected by lymphatic filariasis.
Components
| Condition | Management |
|---|---|
| Lymphedema | Limb hygiene (washing with soap and water), exercises, elevation, skin care to prevent bacterial entry points — reduces acute dermatolymphangioadenitis (ADLA) attacks |
| Hydrocele | Surgical correction (hydrocelectomy) |
| Acute attacks (ADLA) | Antibiotics, antipyretics, limb elevation, wound care |
| Chyluria | Dietary modifications, medium-chain triglycerides, surgery in refractory cases |
| Tropical pulmonary eosinophilia | DEC treatment |
Disability Prevention
- Community-based self-care groups
- Integration with leprosy and NTD disability programmes
- Psychosocial support and economic rehabilitation
Summary Table
| Feature | Pillar 1 (MDA) | Pillar 2 (MMDP) |
|---|---|---|
| Goal | Stop transmission | Reduce suffering |
| Target | Entire at-risk community | Already-affected individuals |
| Tool | DEC + Albendazole / Ivermectin | Hygiene, surgery, rehabilitation |
| Timeframe | Until elimination threshold reached | Ongoing — even post-elimination |
| Indicator | Microfilaremia prevalence <1% | Number receiving care |
Key principle: MDA alone cannot undo existing damage — MMDP is not optional. Both pillars must run simultaneously for the elimination programme to succeed (WHO GPELF 2021–2030).
Sources: WHO Malaria Surveillance Toolkit (p. 253); WHO Guidelines for Treatment of Malaria; Malaria textbook (p. 191); WHO Global Programme to Eliminate Lymphatic Filariasis; NVBDCP National Drug Policy; Park's Textbook of Preventive & Social Medicine.
This is a shared conversation. Sign in to Orris to start your own chat.